Document Detail


Controlled release of insulin from self-assembling nanofiber hydrogel, PuraMatrix™: Application for the subcutaneous injection in rats.
MedLine Citation:
PMID:  22064453     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The concept of this research is, using the acetyl-(Arg-Ala-Asp-Ala)(4)-CONH(2) peptide hydrosol (PuraMatrix™, PM), to develop an new injectable formula of controlled insulin delivery for subcutaneous injection. PM has sol-gel phase transition behavior, and was developed as a scaffold in the field of tissue engineering. The aqueous media of the PM including insulin changed from a sol to a gel phase with increasing ion strength of phosphate ion and pH in working environments in vitro and in vivo. In this study, we examined the in vitro insulin dissolution behavior and the in vivo pharmacokinetics and pharmacodynamics after subcutaneous administration of PM-insulin sol (PM-Isol). In the in vitro release study, after PM-Isol was converted to a gel phase (PM-Igel), PM concentration-dependent and controlled release of insulin were observed at the final concentrations of PM between 0.1% and 2.0% (w/v). The PM-Isol is changed to gel form in vivo, and exhibited a sustained-release pharmacokinetics of insulin, where PM concentration-dependent prolongation of efficacy was found. The plasma glucose level markedly decreased, and the lowest plasma glucose level was maintained up to 24h when 2.0% (w/v) PM-Isol was administered subcutaneously to rats. The PM-Isol, we developed here, is applicable for the wild-type of insulin, and increased the bioavailability and hypoglycemic efficacy of insulin after subcutaneous injection. Hence, the PM is a useful inactive ingredient to produce various types of control-released system of insulin by making just a few changes in PM content of the formulation.
Authors:
Asako Nishimura; Taro Hayakawa; Yu Yamamoto; Mami Hamori; Keiko Tabata; Keiko Seto; Nobuhito Shibata
Related Documents :
8125273 - Genetic influences on glucose neurotoxicity, aging, and diabetes: a possible role for g...
10997603 - Vascular actions of insulin in obesity.
10966133 - The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima afte...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-28
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  -     ISSN:  1879-0720     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier B.V.
Affiliation:
Department of Biopharmaceutics, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto 610-0395, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  All-trans retinoic acid loaded block copolymer nanoparticles efficiently induce cellular differentia...
Next Document:  Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via he...